Department of Neurosurgery, David Geffen School of Medicine, University of California Los Angeles, 300 Stein Plaza Driveway, Suite 420, Los Angeles, CA 90095-1714, USA.
Department of Radiation Oncology, David Geffen School of Medicine, University of California Los Angeles, 10833 Le Conte Avenue, Los Angeles, CA 90095-1714, USA; Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA, USA.
Neurosurg Clin N Am. 2021 Apr;32(2):283-289. doi: 10.1016/j.nec.2021.01.002. Epub 2021 Feb 18.
Only a small fraction of the tumor cell population, glioma-initiating cells (GICs) help glioblastoma propagate, invade, evade immune recognition, repair DNA in response to radiation more efficiently, remodel the microenvironment for optimal growth, and actively pump out chemotherapies. Recent data hint that efforts toward GIC characterization and quantification can help predict patient outcomes, and yet the different subpopulations of GICs remain incompletely understood. A better understanding of GIC subtypes and functions proves critical for engineering targeted therapies. Challenges for doing so are discussed, and dopamine receptor antagonists are introduced as new means to enhance the efficacy of the current standard-of-care against GICs.
只有肿瘤细胞群体中的一小部分，即神经胶质瘤起始细胞（GICs）有助于神经胶质瘤的增殖、侵袭、逃避免疫识别、更有效地修复辐射引起的 DNA 损伤、重塑微环境以促进最佳生长，并主动排出化疗药物。最近的数据表明，对 GIC 特征和定量的研究有助于预测患者的预后，但 GIC 的不同亚群仍不完全了解。更好地了解 GIC 亚型和功能对于设计靶向治疗至关重要。本文讨论了面临的挑战，并介绍了多巴胺受体拮抗剂作为提高当前针对 GIC 标准治疗方法疗效的新方法。
